Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3471-3477

  Chhabra, Arvind ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; WESTERN BLOTTING;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; GENETIC ENGINEERING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MART-1 ANTIGEN; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; TRANSGENES;

EID: 84884251082     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202350     Document Type: Article

References (41)

1. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155: 768-782.
2. Bevan, M. J. 2004. Helping the CD8+ T-cell response. Nat. Rev. Immunol. 4: 595-602.
3. Ruiter, D. J., V. Mattijssen, E. B. Broecker, and S. Ferrone. 1991. MHC antigens in human melanomas. Semin. Cancer Biol. 2: 35-45.
4. Guerry, D., IV, M. A. Alexander, D. E. Elder, and M. F. Herlyn. 1987. Interferong regulates the T cell response to precursor nevi and biologically early melanoma. J. Immunol. 139: 305-312.
5. Andalib, A. R., J. Lawry, S. A. Ali, A. K. Murray, K. Sisley, P. Silcocks, M. Herlyn, and R. C. Rees. 1997. Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res. 7: 32-42.
6. Seliger, B., M. J. Maeurer, and S. Ferrone. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21: 455-464.
7. Chhabra, A., L. Yang, P. Wang, B. Comin-Anduix, R. Das, N. G. Chakraborty, S. Ray, S. Mehrotra, H. Yang, C. L. Hardee, et al. 2008. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J. Immunol. 181: 1063-1070.
8. Ray, S., A. Chhabra, N. G. Chakraborty, U. Hegde, D. I. Dorsky, T. Chodon, E. von Euw, B. Comin-Anduix, R. C. Koya, A. Ribas, et al. 2010. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 136: 338-347.
9. Chhabra, A. 2009. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy. Endocr. Metab. Immune Disord. Drug Targets 9: 344-352.
10. Mehrotra, S., A. Chhabra, S. Chattopadhyay, D. I. Dorsky, N. G. Chakraborty, and B. Mukherji. 2004. Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. J. Immunol. 173: 6017-6024.
11. Chhabra, A., S. Mehrotra, N. G. Chakraborty, B. Mukherji, and D. I. Dorsky. 2004. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur. J. Immunol. 34: 2824-2833.
12. Chhabra, A., N. G. Chakraborty, and B. Mukherji. 2008. Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin. Immunol. 126: 251-259.
13. Chhabra, A., S. Mehrotra, N. G. Chakraborty, D. I. Dorsky, and B. Mukherji. 2006. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. Eur. J. Immunol. 36: 3167-3174.
14. Chhabra, A. 2010. Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine 28: 4566-4572.
15. Chipuk, J. E., and D. R. Green. 2003. p53's believe it or not: lessons on transcription-independent death. J. Clin. Immunol. 23: 355-361.
16. Moll, U. M., S. Wolff, D. Speidel, and W. Deppert. 2005. Transcriptionindependent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17: 631-636.
17. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
18. Janssen, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and S. P. Schoenberger. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856.
19. Sun, J. C., M. A. Williams, and M. J. Bevan. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5: 927-933.
20. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
21. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
22. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
23. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
24. Rosenberg, S. A., M. E. Dudley, and N. P. Restifo. 2008. Cancer immunotherapy. N. Engl. J. Med. 359: 1072.
25. Sadelain, M. 2009. T-cell engineering for cancer immunotherapy. Cancer J. 15: 451-455.
26. Chhabra, A. 2011. TCR-engineered, customized, antitumor T cells for cancer immunotherapy: advantages and limitations. ScientificWorldJournal 11: 121-129.
27. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513.
28. Heemskerk, M. H., M. Hoogeboom, R. Hagedoorn, M. G. Kester, R. Willemze, and J. H. Falkenburg. 2004. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199: 885-894.
29. Tsuji, T., M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, et al. 2005. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106: 470-476.
30. Willemsen, R., C. Ronteltap, M. Heuveling, R. Debets, and R. Bolhuis. 2005. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR ab gene transfer requires CD8a. Gene Ther. 12: 140-146.
31. Kennedy, R., and E. Celis. 2006. T helper lymphocytes rescue CTL from activation-induced cell death. J. Immunol. 177: 2862-2872.
32. Ashwell, J. D., R. E. Cunningham, P. D. Noguchi, and D. Hernandez. 1987. Cell growth cycle block of T cell hybridomas upon activation with antigen. J. Exp. Med. 165: 173-194.
33. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in Tcell hybridomas. Nature 373: 441-444.
34. Dhein, J., H. Walczak, C. Bäumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441.
35. Shi, Y. F., B. M. Sahai, and D. R. Green. 1989. Cyclosporin A inhibits activationinduced cell death in T-cell hybridomas and thymocytes. Nature 339: 625-626.
36. Dumont, C., A. Dürrbach, N. Bidère, M. Rouleau, G. Kroemer, G. Bernard, F. Hirsch, B. Charpentier, S. A. Susin, and A. Senik. 2000. Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult. Blood 96: 1030-1038.
37. Jäättelä,M., and J. Tschopp. 2003. Caspase-independent cell death in T lymphocytes. Nat. Immunol. 4: 416-423.
38. Walker, L. S., J. D. McLeod, G. Boulougouris, Y. I. Patel, C. N. Ellwood, N. D. Hall, and D. M. Sansom. 1999. Lack of activation induced cell death in human T blasts despite CD95L up-regulation: protection from apoptosis by MEK signalling. Immunology 98: 569-575.
39. Green, D. R., and J. C. Reed. 1998. Mitochondria and apoptosis. Science 281: 1309-1312.
40. Penninger, J. M., and G. Kroemer. 2003. Mitochondria, AIF and caspases-rivaling for cell death execution. Nat. Cell Biol. 5: 97-99.
41. Strom, E., S. Sathe, P. G. Komarov, O. B. Chernova, I. Pavlovska, I. Shyshynova, D. A. Bosykh, L. G. Burdelya, R. M. Macklis, R. Skaliter, et al. 2006. Smallmolecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2: 474-479.